Company News - China Railway Construction Corporation (01186.HK) reported a total new contract value of 1,518.765 billion yuan for the first three quarters, an increase of 3.08% year-on-year. The new contract value for the third quarter was 462.5954 billion yuan [2] - Zhiyu City Technology (09911.HK) expects total revenue from its social business for the first nine months to be between 4.38 billion and 4.44 billion yuan, representing a year-on-year growth of approximately 34.5% to 36.4%. The innovative business revenue is projected to be between 530 million and 550 million yuan, with a year-on-year growth of about 69.9% to 76.3% [2] - Ping An Good Doctor (01833.HK) reported total revenue of 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and a net profit of 184 million yuan, up 72.6% year-on-year. The company's F-end and B-end enterprise health business revenue grew by 21.5% year-on-year, serving over 4,500 corporate clients [3] - Livzon Pharmaceutical (01513.HK) reported revenue of 9.116 billion yuan for the first three quarters, an increase of 0.38% year-on-year, and a net profit of 1.754 billion yuan, up 4.86% year-on-year [3] - Mongolian Energy (00276.HK) reported a significant decrease in total revenue for the six months ending September 30, 2025, by no more than 900 million HKD, primarily due to global economic recession and a slowdown in the Chinese steel market [3] - Anning Holdings (00128.HK) issued a profit warning, expecting a profit of approximately 21 million HKD for the first three quarters, a significant turnaround from a loss [3] - Baio Family Interactive (02100.HK) reported 10.2 million active accounts in the third quarter, a quarter-on-quarter increase of 29.1% and a year-on-year increase of 37.8%. The average revenue per paid account was 141.2 yuan, down 19.2% quarter-on-quarter and 13.2% year-on-year [3] - Hengrui Medicine (01276.HK) received approval to conduct clinical trials for its injection of Rukang Qutuzumab, with global sales of similar products totaling approximately 6.557 billion USD [4] - Baixin An-B (02185.HK) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [5] - Hansoh Pharmaceutical (03692) had its application for marketing approval of HS-10365 capsules accepted by the National Medical Products Administration [6] Capital Operations and Buyback Dynamics - Minmetals Land (00230.HK) received a privatization offer from Minmetals Hong Kong, with the offer price representing a premium of 185.71% over the undisturbed closing price [7] - Qizhi Group (00917.HK) received a voluntary lock-up commitment from directors and concert parties, with a lock-up period of 12 months starting from October 23, 2025, involving 103 million shares of the company [7] - Mengniu Dairy (02319.HK) repurchased 700,000 shares at a cost of 10.0692 million HKD, with a repurchase price of 14.33 to 14.4 HKD [7] - Lianlian Digital (02598.HK) repurchased approximately 755.55 million HKD worth of 967,000 shares, with a repurchase price of 7.63 to 7.96 HKD [8]